Humana shares rise after insurer says medical costs came in lower than expected

Humana shares rise after insurer says medical costs came in lower than expected


A Humana office in Louisville, Kentucky, July 31, 2023.

Jon Cherry | Bloomberg | Getty Images

Humana shares rose Wednesday after the health insurer said medical costs came in lower than expected during its second-quarter earnings report.

The results ease investor concerns two months after Humana and rival UnitedHealth Group warned that a surge in demand for nonurgent surgeries and outpatient services among seniors was driving up claims. 

Both companies — the two biggest providers of Medicare Advantage plans for people ages 65 and above — have now suggested the uptick may be abating. 

Humana reported a medical loss ratio, the percentage of premiums it spends on medical care, of 86.3% for the second quarter. Analysts had estimated that ratio would be 86.5%, according to Refinitiv data.

Humana highlighted a “stabilizing Medicare Advantage utilization environment” based on the most recent claims activity, without elaborating.

The company said in June it expected its second-quarter medical loss ratio to be toward the top range of its full-year outlook of 86.3% to 87.3%. Humana reiterated that full-year guidance Wednesday.

Humana’s stock rose 5% in morning trading Wednesday. Shares are down about 5% for the year after the broader health-care sector took a beating in June, putting the company’s market value at around $60 billion.



Source

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound
Health

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound

Cr | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, […]

Read More
FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says
Health

FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says

The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC on Friday.  The FDA in June announced a national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are […]

Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Health

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January. “Canada is […]

Read More